Gene by Gene

GeneByGene.com

The most complete family of integrated multi-disciplinary genetic testing services, with state-of-the-art laboratory and capabilities. Gene by Gene, through its division Family Tree DNA was the first company in the world to develop DNA testing for ancestry and genealogical purposes as a commercial application. Prior to the company’s initiative, these tests were only available for academic and research purposes. Because of this innovation, it was selected by the National Geographic Society and its partner, IBM, to provide the testing and manage all public participation in the Genographic Project. Initially, the Arizona Research Labs at The University of Arizona performed all testing. In 2006, Gene by Gene established a state-of-the-art Genomics Research Center at its headquarters in Houston, Texas, where it currently performs R&D and processes over 200 types of DNA tests for its customers, ranging from individuals to physicians, hospitals, universities and research institutions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

QIAGEN AND HELIX PARTNER TO ADVANCE COMPANION DIAGNOSTICS FOR HEREDITARY DISEASES

QIAGEN | January 06, 2023

news image

QIAGEN recently announced an exclusive strategic partnership with Helix, a California population genomics leader, to advance companion diagnostics for hereditary diseases. The requirement for companion diagnostic devices and tests capable of detecting clinically relevant genetic abnormalities grows along with the accelerated development of precision medicines. These tests helps in making decisions by showing patients that are most likely to benefit from a specific therapeutic prod...

Read More

Industrial Impact

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

news image

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More

Medical

SELFDECODE OFFERS FREE KIDNEY HEALTH DNA REPORT TO CELEBRATE NATIONAL KIDNEY MONTH

SELFDECODE | March 07, 2022

news image

SelfDecode is kicking off National Kidney Month with a national campaign to raise awareness about the importance of preventative measures to optimize kidney health. For the month of March, SelfDecode is offering a free Kidney Health DNA Report to anyone who uploads a DNA file for analysis. Through genetic testing, SelfDecode is providing people with the opportunity to gain insight regarding their genetic predisposition for health issues and receive personalized recommendations to ...

Read More

Cell and Gene Therapy

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen | June 23, 2021

news image

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

Read More
news image

MedTech, Industrial Impact

QIAGEN AND HELIX PARTNER TO ADVANCE COMPANION DIAGNOSTICS FOR HEREDITARY DISEASES

QIAGEN | January 06, 2023

QIAGEN recently announced an exclusive strategic partnership with Helix, a California population genomics leader, to advance companion diagnostics for hereditary diseases. The requirement for companion diagnostic devices and tests capable of detecting clinically relevant genetic abnormalities grows along with the accelerated development of precision medicines. These tests helps in making decisions by showing patients that are most likely to benefit from a specific therapeutic prod...

Read More
news image

Industrial Impact

CANTARGIA TO HOLD WEBCAST BRIEFING ON RECENTLY ANNOUNCED RIGHTS ISSUE

Cantargia AB | July 05, 2022

Cantargia AB issued an invitation to attend a webcast on its recently announced fully covered rights issue. The text of the invitation is as follows Cantargia invites you to register for and attend an online briefing on Cantargia's recently announced fully covered rights issue intended to raise approximately SEK 250 million in additional capital. Cantargia's lead asset, nadunolimab has shown very promising efficacy results in phase IIa studies in over 70 PDA...

Read More
news image

Medical

SELFDECODE OFFERS FREE KIDNEY HEALTH DNA REPORT TO CELEBRATE NATIONAL KIDNEY MONTH

SELFDECODE | March 07, 2022

SelfDecode is kicking off National Kidney Month with a national campaign to raise awareness about the importance of preventative measures to optimize kidney health. For the month of March, SelfDecode is offering a free Kidney Health DNA Report to anyone who uploads a DNA file for analysis. Through genetic testing, SelfDecode is providing people with the opportunity to gain insight regarding their genetic predisposition for health issues and receive personalized recommendations to ...

Read More
news image

Cell and Gene Therapy

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen | June 23, 2021

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

Read More